{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T21:25:01Z","timestamp":1772313901984,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011240","name":"Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Foundation","doi-asserted-by":"publisher","award":["SUFU Foundation Study of Chemodenervation"],"award-info":[{"award-number":["SUFU Foundation Study of Chemodenervation"]}],"id":[{"id":"10.13039\/100011240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH 1L30DK115056-01"],"award-info":[{"award-number":["NIH 1L30DK115056-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Stanford Women\u2019s Health and Sex Differences in Medicine","award":["Seed Grant for Biological\/Medical Research on Sex Differences and\/or Women\u2019s Health"],"award-info":[{"award-number":["Seed Grant for Biological\/Medical Research on Sex Differences and\/or Women\u2019s Health"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00192-021-04878-9","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T09:02:47Z","timestamp":1624352567000},"page":"3105-3111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Trigone as a diagnostic and therapeutic target for bladder-centric interstitial cystitis\/bladder pain syndrome"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3451-3878","authenticated-orcid":false,"given":"Amy D.","family":"Dobberfuhl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4484-5489","authenticated-orcid":false,"given":"Stefanie","family":"van Uem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-7370","authenticated-orcid":false,"given":"Eboo","family":"Versi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"4878_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.juro.2011.03.132","volume":"186","author":"SH Berry","year":"2011","unstructured":"Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, et al. Prevalence of symptoms of bladder pain syndrome\/interstitial cystitis among adult females in the United States. J Urol. 2011;186:540\u20134. https:\/\/doi.org\/10.1016\/j.juro.2011.03.132.","journal-title":"J Urol"},{"key":"4878_CR2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","volume":"193","author":"PM Hanno","year":"2015","unstructured":"Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological Association. Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545\u201353. https:\/\/doi.org\/10.1016\/j.juro.2015.01.086.","journal-title":"J Urol"},{"key":"4878_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.urology.2006.08.1108","volume":"69","author":"O Nazif","year":"2007","unstructured":"Nazif O, Teichman JMH, Gebhart GF. Neural upregulation in interstitial cystitis. Urology. 2007;69:24\u201333. https:\/\/doi.org\/10.1016\/j.urology.2006.08.1108.","journal-title":"Urology"},{"key":"4878_CR4","doi-asserted-by":"publisher","first-page":"760.e1","DOI":"10.1016\/j.ajog.2016.07.023","volume":"215","author":"A Yosef","year":"2016","unstructured":"Yosef A, Allaire C, Williams C, Ahmed AG, Al-Hussaini T, Abdellah MS, et al. Multifactorial contributors to the severity of chronic pelvic pain in women. Am J Obstet Gynecol. 2016;215:760.e1\u2013760.e14. https:\/\/doi.org\/10.1016\/j.ajog.2016.07.023.","journal-title":"Am J Obstet Gynecol"},{"key":"4878_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrn2401","volume":"9","author":"CJ Fowler","year":"2008","unstructured":"Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9:453\u201366. https:\/\/doi.org\/10.1038\/nrn2401.","journal-title":"Nat Rev Neurosci"},{"key":"4878_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.juro.2017.02.022","volume":"198","author":"SJ Walker","year":"2017","unstructured":"Walker SJ, Zambon J, Andersson K-E, Langefeld CD, Matthews CA, Badlani G, et al. Bladder capacity is a biomarker for a bladder centric versus systemic manifestation in interstitial cystitis\/bladder pain syndrome. J Urol. 2017;198:369\u201375. https:\/\/doi.org\/10.1016\/j.juro.2017.02.022.","journal-title":"J Urol"},{"key":"4878_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1442-2042.2011.02749.x","volume":"18","author":"A Fujihara","year":"2011","unstructured":"Fujihara A, Ukimura O, Iwata T, Miki T. Neuroselective measure of the current perception threshold of A-delta and C-fiber afferents in the lower urinary tract. Int J Urol. 2011;18:341\u20139. https:\/\/doi.org\/10.1111\/j.1442-2042.2011.02749.x.","journal-title":"Int J Urol"},{"key":"4878_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/nau.21194","volume":"31","author":"G Vijaya","year":"2012","unstructured":"Vijaya G, Digesu GA, Derpapas A, Hendricken C, Fernando R, Khullar V. Antimuscarinic effects on current perception threshold: a prospective placebo control study. Neurourol Urodyn. 2012;31:75\u20139. https:\/\/doi.org\/10.1002\/nau.21194.","journal-title":"Neurourol Urodyn"},{"key":"4878_CR9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.urology.2015.01.021","volume":"85","author":"RA Henry","year":"2015","unstructured":"Henry RA, Morales A, Cahill CM. Beyond a simple anesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis\/bladder pain syndrome. Urology. 2015;85:1025\u201333. https:\/\/doi.org\/10.1016\/j.urology.2015.01.021.","journal-title":"Urology"},{"key":"4878_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000000972","author":"TL Overholt","year":"2020","unstructured":"Overholt TL, Matthews CA, Evans RJ, Badlani G, Ahn C, Simon T, et al. Small fiber polyneuropathy is associated with non-bladder-centric interstitial cystitis\/bladder pain syndrome patients. Female Pelvic Med Reconstr Surg. 2020. https:\/\/doi.org\/10.1097\/SPV.0000000000000972.","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"4878_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.juro.2017.10.018","volume":"199","author":"RA Pinto","year":"2018","unstructured":"Pinto RA, Costa D, Morgado A, Pereira P, Charrua A, Silva J, et al. Intratrigonal OnabotulinumtoxinA improves bladder symptoms and quality of life in patients with bladder pain syndrome\/interstitial cystitis: a pilot, single center, randomized, double-blind, placebo controlled trial. J Urol. 2018;199:998\u20131003. https:\/\/doi.org\/10.1016\/j.juro.2017.10.018.","journal-title":"J Urol"},{"key":"4878_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/nau.22760","volume":"35","author":"H-C Kuo","year":"2016","unstructured":"Kuo H-C, Jiang Y-H, Tsai Y-C, Kuo Y-C. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment\u2014a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016;35:609\u201314. https:\/\/doi.org\/10.1002\/nau.22760.","journal-title":"Neurourol Urodyn"},{"key":"4878_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/iju.12833","volume":"22","author":"Y Akiyama","year":"2015","unstructured":"Akiyama Y, Nomiya A, Niimi A, Yamada Y, Fujimura T, Nakagawa T, et al. Botulinum toxin type A injection for refractory interstitial cystitis: a randomized comparative study and predictors of treatment response. Int J Urol. 2015;22:835\u201341. https:\/\/doi.org\/10.1111\/iju.12833.","journal-title":"Int J Urol"},{"key":"4878_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","volume":"104","author":"H-C Kuo","year":"2009","unstructured":"Kuo H-C, Chancellor MB. Comparison of intravesical botulinum toxin type a injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome. BJU Int. 2009;104:657\u201361. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08495.x.","journal-title":"BJU Int"},{"issue":"6","key":"4878_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11255-021-02802-0","volume":"53","author":"J Ton","year":"2021","unstructured":"Ton J, Downing P, Versi E, van Uem S, Ephraim S, Murphy M, et al. Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB). Int Urol Nephrol. 2021;53(6):1067\u201372","journal-title":"Int Urol Nephrol"},{"key":"4878_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s11255-015-0976-2","volume":"47","author":"M Alsinnawi","year":"2015","unstructured":"Alsinnawi M, Torreggiani W, Sheikh M, Thomas A, Donnellan J, Flynn R, et al. Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection. Int Urol Nephrol. 2015;47:893\u20138. https:\/\/doi.org\/10.1007\/s11255-015-0976-2.","journal-title":"Int Urol Nephrol"},{"key":"4878_CR17","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/nau.21054","volume":"30","author":"H-C Kuo","year":"2011","unstructured":"Kuo H-C. Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30:1242\u20138. https:\/\/doi.org\/10.1002\/nau.21054.","journal-title":"Neurourol Urodyn"},{"key":"4878_CR18","doi-asserted-by":"publisher","first-page":"668.e1","DOI":"10.1016\/j.ajog.2007.08.068","volume":"197","author":"DD Rahn","year":"2007","unstructured":"Rahn DD, Bleich AT, Wai CY, Roshanravan SM, Wieslander CK, Schaffer JI, et al. Anatomic relationships of the distal third of the pelvic ureter, trigone, and urethra in unembalmed female cadavers. Am J Obstet Gynecol. 2007;197:668.e1\u20134. https:\/\/doi.org\/10.1016\/j.ajog.2007.08.068.","journal-title":"Am J Obstet Gynecol"},{"key":"4878_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7863\/jum.2003.22.8.777","volume":"22","author":"J-M Yang","year":"2003","unstructured":"Yang J-M, Huang W-C. Bladder wall thickness on ultrasonographic cystourethrography: affecting factors and their implications. J Ultrasound Med. 2003;22:777\u201382. https:\/\/doi.org\/10.7863\/jum.2003.22.8.777.","journal-title":"J Ultrasound Med"},{"key":"4878_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00192-010-1183-4","volume":"21","author":"DC Panayi","year":"2010","unstructured":"Panayi DC, Digesu GA, Tekkis P, Fernando R, Khullar V. Ultrasound measurement of vaginal wall thickness: a novel and reliable technique. Int Urogynecol J. 2010;21:1265\u201370. https:\/\/doi.org\/10.1007\/s00192-010-1183-4.","journal-title":"Int Urogynecol J"},{"key":"4878_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4111\/icu.2019.60.1.40","volume":"60","author":"R Syan","year":"2019","unstructured":"Syan R, Briggs MA, Olivas JC, Srivastava S, Comiter CV, Dobberfuhl AD. Transvaginal ultrasound guided trigone and bladder injection: a cadaveric feasibility study for a novel route of intradetrusor chemodenervation. Investig Clin Urol. 2019;60:40\u20135. https:\/\/doi.org\/10.4111\/icu.2019.60.1.40.","journal-title":"Investig Clin Urol"},{"key":"4878_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/01.ju.0000025438.77821.93","volume":"168","author":"OL Westney","year":"2002","unstructured":"Westney OL, Lee JT, McGuire EJ, Palmer JL, Cespedes RD, Amundsen CL. Long-term results of Ingelman-Sundberg denervation procedure for urge incontinence refractory to medical therapy. J Urol. 2002;168:1044\u20137. https:\/\/doi.org\/10.1097\/01.ju.0000025438.77821.93.","journal-title":"J Urol"},{"key":"4878_CR23","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1097\/01.ju.0000142016.51680.fa","volume":"172","author":"Y Lotan","year":"2004","unstructured":"Lotan Y, Cadeddu JA, Roehrborn CG, Stage KH. The value of your time: evaluation of effects of changes in Medicare reimbursement rates on the practice of urology. J Urol. 2004;172:1958\u201362. https:\/\/doi.org\/10.1097\/01.ju.0000142016.51680.fa.","journal-title":"J Urol"},{"key":"4878_CR24","first-page":"474","volume":"6","author":"K Stav","year":"2004","unstructured":"Stav K, Leibovici D, Goren E, Livshitz A, Siegel YI, Lindner A, et al. Adverse effects of cystoscopy and its impact on patients\u2019 quality of life and sexual performance. Isr Med Assoc J. 2004;6:474\u20138.","journal-title":"Isr Med Assoc J"},{"key":"4878_CR25","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00192-015-2751-4","volume":"26","author":"N Chohan","year":"2015","unstructured":"Chohan N, Hilton P, Brown K, Dixon L. Efficacy and duration of response to botulinum neurotoxin a (onabotulinumA) as a treatment for detrusor overactivity in women. Int Urogynecol J. 2015;26:1605\u201312. https:\/\/doi.org\/10.1007\/s00192-015-2751-4.","journal-title":"Int Urogynecol J"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-021-04878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-021-04878-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-021-04878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T09:05:07Z","timestamp":1638522307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-021-04878-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4878"],"URL":"https:\/\/doi.org\/10.1007\/s00192-021-04878-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740347662.793586806","asserted-by":"object"}]},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"17 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Dobberfuhl is an investigator for the SUFU Foundation seed grant entitled \u201cFeasibility and efficacy of transvaginal onabotulinumtoxinA chemodenervation of the trigone for the third line treatment of refractory overactive bladder.\u201d S. van Uem declares no conflicts of interest in relation to the content of the manuscript. E. Versi is the inventor of patent USPTO #8,029,496 entitled \u201cMethod and device for delivering drug to the trigone of the bladder\u201d and consultant for Hologic Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}